Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

(2020) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma

(2020) Min Yuen Teo et al.   EUROPEAN UROLOGY

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†

(2020) Bas W.G. van Rhijn et al.   EUROPEAN UROLOGY

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

Diagnostic and Prognostic Implications of FGFR3high/Ki67high Papillary Bladder Cancers

(2018) Mirja Geelvink et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: A systematic review and meta-analysis

(2018) Shoji Kimura et al.   JOURNAL OF UROLOGY

p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant

(2017) Anjelica Hodgson et al.   HISTOPATHOLOGY

Tumor heterogeneity offibroblast growth factor receptor 3(FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment

(2016) D. Pouessel et al.   ANNALS OF ONCOLOGY

The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder

(2016) Romain Mathieu et al.   Nature Reviews Urology

Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis

(2016) Yuejun Tian et al.   PLoS One

Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics

(2015) Kelly Elliott et al.   JOURNAL OF CLINICAL PATHOLOGY

Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice

(2014) Bas W.G. van Rhijn et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy

(2013) Yair Lotan et al.   EUROPEAN UROLOGY